Business Description
Daan Gene Co Ltd
NAICS : 325199
ISIN : CNE000001KP1
Share Class Description:
SZSE:002030: Class ACompare
Compare
Traded in other countries / regions
002030.China IPO Date
2004-08-09Description
Daan Gene Co Ltd is a high-tech enterprise-oriented in molecular diagnostic techniques. It is primarily committed to research and development, production, and service of in-vitro diagnostic products, including qPCR, Sequeacing, TRF, ELISA, and Liquid-Based Cytology diagnostic kits and equipment. Geographically, tahe group operates in China.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.33 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | 0.38 | |||||
| Interest Coverage | 84 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 6.4 | |||||
| Beneish M-Score | -2.43 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 122.1 | |||||
| 3-Year EBITDA Growth Rate | 273.1 | |||||
| 3-Year EPS without NRI Growth Rate | 672.8 | |||||
| 3-Year Book Growth Rate | 83.1 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.93 | |||||
| 9-Day RSI | 53.49 | |||||
| 14-Day RSI | 55.88 | |||||
| 6-1 Month Momentum % | -20.42 | |||||
| 12-1 Month Momentum % | -45.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.94 | |||||
| Quick Ratio | 2.72 | |||||
| Cash Ratio | 0.65 | |||||
| Days Inventory | 128.02 | |||||
| Days Sales Outstanding | 352.95 | |||||
| Days Payable | 177.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 16.89 | |||||
| Dividend Payout Ratio | 2.88 | |||||
| 3-Year Dividend Growth Rate | 264.1 | |||||
| Forward Dividend Yield % | 16.89 | |||||
| 5-Year Yield-on-Cost % | 1024.63 | |||||
| Shareholder Yield % | 18.29 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 64.35 | |||||
| Operating Margin % | 31.84 | |||||
| Net Margin % | 24.04 | |||||
| FCF Margin % | 21.7 | |||||
| ROE % | 8.24 | |||||
| ROA % | 6.52 | |||||
| ROIC % | 11.96 | |||||
| ROC (Joel Greenblatt) % | 19.1 | |||||
| ROCE % | 8.19 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 17.22 | |||||
| PE Ratio without NRI | 12.88 | |||||
| Shiller PE Ratio | 11.51 | |||||
| Price-to-Owner-Earnings | 55.1 | |||||
| PEG Ratio | 0.1 | |||||
| PS Ratio | 4.15 | |||||
| PB Ratio | 1.61 | |||||
| Price-to-Tangible-Book | 1.78 | |||||
| Price-to-Free-Cash-Flow | 19.1 | |||||
| Price-to-Operating-Cash-Flow | 9.41 | |||||
| EV-to-EBIT | 15.52 | |||||
| EV-to-EBITDA | 15.52 | |||||
| EV-to-Revenue | 3.87 | |||||
| EV-to-FCF | 18.13 | |||||
| Price-to-Projected-FCF | 0.59 | |||||
| Price-to-DCF (Earnings Based) | 0.41 | |||||
| Price-to-DCF (FCF Based) | 1.66 | |||||
| Price-to-Median-PS-Value | 0.48 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.52 | |||||
| Price-to-Graham-Number | 1.01 | |||||
| Price-to-Net-Current-Asset-Value | 5.13 | |||||
| Earnings Yield (Greenblatt) % | 6.44 | |||||
| FCF Yield % | 5.25 | |||||
| Forward Rate of Return (Yacktman) % | 30.19 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Daan Gene Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 3,552.656 | ||
| EPS (TTM) (Â¥) | 0.608 | ||
| Beta | 0.34 | ||
| Volatility % | 27.32 | ||
| 14-Day RSI | 55.88 | ||
| 14-Day ATR (Â¥) | 0.277177 | ||
| 20-Day SMA (Â¥) | 10.164 | ||
| 12-1 Month Momentum % | -45.68 | ||
| 52-Week Range (Â¥) | 9.15 - 17.98 | ||
| Shares Outstanding (Mil) | 1,403.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Daan Gene Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Daan Gene Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Daan Gene Co Ltd Frequently Asked Questions
What is Daan Gene Co Ltd(SZSE:002030)'s stock price today?
The current price of SZSE:002030 is ¥10.47. The 52 week high of SZSE:002030 is ¥17.98 and 52 week low is ¥9.15.
When is next earnings date of Daan Gene Co Ltd(SZSE:002030)?
The next earnings date of Daan Gene Co Ltd(SZSE:002030) is .
Does Daan Gene Co Ltd(SZSE:002030) pay dividends? If so, how much?
The Dividend Yield %  of Daan Gene Co Ltd(SZSE:002030) is 16.89% (As of Today), Highest Dividend Payout Ratio of Daan Gene Co Ltd(SZSE:002030) was 2.88. The lowest was 0.01. And the median was 0.28. The  Forward Dividend Yield % of Daan Gene Co Ltd(SZSE:002030) is 16.89%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers